Pursuant to DOH AO No. 2020-0015 known as “Guidelines on the Risk-Based Public Health Standards for COVID-19 Mitigation”, the FDA has been strictly implementing minimum health standards and health safety protocols to prevent the transmission of COVID-19 and other infectious diseases.
The alarming increase in the number of infections due to COVID-19 poses a threat to the health and safety of employees and clients of FDA. With the recent developments and consultation with internal and external stakeholders, the following guidelines shall be enforced to safely continue serving our clients and to ensure the safety of everyone.
The objective for the issuance of this Order is to provide clear and consistent guidelines for the safety of FDA employees and clients in order to prevent infection and the spread of COVID-19 and other infectious diseases at the FDAC.
This Order shall cover all FDA clients from the industries transacting business at the FDAC and FDA employees or staff providing regulatory services at the FDA.
Read more:-> FDA Circular No. 2020-026
Attachment:-> Annex C – Notification Form for Minor Variation/s of Registered Pharmaceutical Product